Background and Aims: Colectomy can be required in the management of ulcerative colitis [UC]. While ileal-pouch anal anastomosis [IPAA] is the recommended reconstruction technique, ileorectal anastomosis [IRA] is still performed and might present some advantages. However, the risk of rectal neoplasia might limit its indication. The aims of our study were to determine the incidence of rectal neoplasias following IRA for UC and to identify risk factors associated with rectal carcinomas. Methods: We performed a multicenter retrospective study including patients who underwent IRA for UC from 1960 to 2014 in 13 centers. Cox-proportional hazard models were used to determine carcinoma-associated risk factors. Results: A total of 343 patients were included, with a median follow-up of 10.4 years after IRA. At the end of follow-up, 38 rectal neoplasias (including 19 carcinomas) were diagnosed, and 7 patients [2%] had either died from rectal carcinoma or had a metastatic disease. Incidences of rectal carcinoma after IRA for UC were estimated at 3.2% at 10 years and at 7.3% at 20 years, whereas incidences of Abbreviations: IBD, Inflammatory bowel diseases; IPAA, Ileal pouch anal-anastomosis; IRA, Ileorectal anastomosis; PSC, Primary sclerosing cholangitis; UC, Ulcerative colitis. neoplasia were estimated at 7.1% and 14% at 10 and 20 years, respectively. In multivariate analysis, age at IRA, IBD duration, primary sclerosing cholangitis [PSC] and history of prior colonic carcinoma were independently associated with the risk of rectal carcinoma following IRA.
Introduction
Despite progress in medical management, colectomy for ulcerative colitis [UC] is still performed in up to 30% of patients. [1] [2] [3] It is required in several circumstances, including refractory disease to medical therapy, and colonic neoplasia. 4 Patients with inflammatory bowel diseases with colonic involvement are at higher risk of developing colonic neoplasia compared with the general population. 5 This potentially lethal complication usually necessitates a colectomy. While ileal-pouch anal anastomosis [IPAA] is recommended by the European current guidelines as the preferential reconstruction technique after colectomy for UC, 6, 7 ileorectal anastomosis [IRA] appears to have some advantages. The latter include a potentially better functional outcome as well as a less complex surgical procedure. 8 However, the fear of the occurrence of a subsequent neoplasia located on the remnant rectum might limit its indications.
To date, only limited knowledge regarding this issue is available, which is gathered in a recent meta-analysis by Derikx et al. 9 The pooled prevalence of rectal neoplasia after colectomy and IRA was 2.4% among 2762 patients, with a reported follow-up ranging from 1 to 35 years. The combined analysis of three widely heterogeneous studies revealed a history of prior colonic carcinoma as a risk factor for developing rectal carcinoma after IRA. 9 Other potential risk factors have never been studied or have been insufficiently studied and reported. Moreover, until recently only one cohort study (including 86 patients) estimated the cumulative incidence of rectal carcinoma after IRA. 10 Therefore, the available evidence regarding the risk of rectal neoplasia after IRA for UC as well as its associated risk factors remains scarce. It is mainly based on historical studies often exhibiting a restricted size cohort, a very variable duration of follow-up, or the occurrence of very few events, thus providing inaccurate and one-dimensional data.
To address these important and clinical practice-oriented questions, we conducted a retrospective study from a large GETAID/ GETAID chirurgie cohort, and our aim was to determine the incidence of rectal neoplasia after colectomy and IRA for UC and to identify risk factors associated with rectal carcinoma.
Methods

Patients
The present cohort of patients has been studied regarding the risk of IRA failure and the results of that study have already been published. 11 The cohort was built from a centralized GETAID/GETAID chirurgie registry. GETAID is a consortium of French and European inflammatory bowel disease [IBD] centers. In the present study, 13 French centers participated and enrolled patients using an online registry. Data were then retrospectively collected from medical records. Colectomies and IRAs were performed from 1960 to 2014, and the last known contact date ranged from 1972 to 2015. Patients were followed until secondary protectomy, death or last known contact date.
Inclusion criteria were as follows: patients who underwent a subtotal colectomy with IRA as the reconstruction technique; patients should be older than 18 years at cohort entry and should have an established diagnosis of UC or indeterminate colitis at the time of the colectomy. Patients with Crohn's disease diagnosed prior to IRA were excluded. There was no limitation on the date of the colectomy and IRA. As no recommendation regarding the frequency of endoscopic surveillance of the remnant rectum is currently available, the endoscopic surveillance of the remnant rectum was performed according to each center's habits. In French tertiary IBD centers, similarly to colonic surveillance, rectal endoscopy is usually performed every 2-3 years in the presence of IRA. 
End points
The primary end point was defined by the occurrence of rectal carcinoma after IRA for UC. Secondary end points were the occurrence of rectal neoplasia [including dysplasia and carcinoma] after IRA. The diagnosis of rectal carcinoma was always confirmed via histological assessment. The presence of prior colonic neoplasia was based upon the pathological findings of the surgical specimen after colectomy.
Since, over the long duration of the study, many changes in definitions, grading and characterization of lesions have occurred, 12 and, as there is a wide interobserver variability in dysplasia evaluation, 13 low-grade and high-grade dysplasia were merged into a unique variable [i.e. 'dysplasia']. 'Indefinite' regarding dysplasia 'was not considered as dysplasia. The concomitant presence of carcinoma and dysplasia was classified as 'carcinoma'. Pathological features were recorded from pathological reports.
Statistics
Quantitative variables are expressed as median (interquartile range [IQR] ). Qualitative variables are given as numbers [percentages] . The comparison of patients' baseline characteristics according to the occurrence of rectal neoplasias was performed using Chi-square tests for qualitative variables and with a Student t test for quantitative variables. Cumulative incidences of neoplasias were assessed using a Kaplan-Meier analysis. We used a logrank test to compare survival among various subgroups. In order to identify predictors of rectal carcinoma after IRA, a Cox proportional hazards regression analysis was performed.
Variables significant at p < 0.20 in the univariate analysis were entered into a multivariate Cox proportional hazards regression model, with a backward variable elimination procedure to assess the strength of the associations, while controlling for possible 
Results
Background characteristics
We included 343 patients from 13 centers. The median follow-up after IRA was 10.4 years (IQR [4.4-18.4] ). General baseline characteristics with respect to the occurrence of rectal neoplasia are displayed in Table 1 
Characteristics of patients with post-IRA incidental rectal carcinoma
The characteristics of patients with rectal carcinomas are displayed in Table 2 
Risk factors associated with rectal carcinoma
First, we performed a univariate Cox model analysis to assess for factors associated with post-IRA incidental rectal carcinoma [ Table 3 ]. As previous colonic neoplasia appeared as an associated factor for rectal carcinoma after IRA, we assessed the cumulative incidences of rectal carcinoma and rectal neoplasia according to the presence/ absence of a history of colonic dysplasia or carcinoma. The 10-year estimated cumulative incidence of rectal neoplasia was 30.0% [95% CI [0.8-60.8]) for patients with previous colonic dysplasia, 50.5% (95% CI [3.5-86.9]) for patients with previous colonic carcinoma and 6.0% (95% CI [3.4-9.6]) for patients without previous colonic neoplasia Figure 2 . Regarding the risk of rectal carcinoma, the cumulative incidence at 10 years after IRA was estimated at 25.0% (95% [CI 0.4-57.4]), 50.5% (95% CI [3.5-86.9]) and 2.1% (95% CI [0.8-4.6]) for patients with previous colonic dysplasia, carcinoma or without previous colonic neoplasia, respectively [ Figure 3] .
Further, using a multivariate Cox model after backward elimination of non-significant variables, we determined that age at IRA, IBD duration, PSC, as well as the history of prior colonic carcinoma at the time of the colectomy, were independently associated with the risk of developing a rectal carcinoma after colectomy and IRA [ Table 3 ]. In multivariate analysis, the period of the IRA confection was not associated with the risk of rectal carcinoma (<1990 as 
Discussion
In the present study, we report an overall cumulative incidence of rectal carcinoma at 3.2% at 10 years and at 7.3% at 20 years following IRA for UC. Age, IBD duration, PSC, and a prior colonic carcinoma were independently associated with a higher risk. These results were based on a multicenter cohort with a long median follow-up of >10 years. Therefore, the high number of reported rectal carcinomas [19 events] makes our findings accurate and reliable regarding estimated long-term incidences and risk factors. Previously reported cumulative incidences are detailed in Table 4 . Abdalla et al. recently reported the data from a Swedish nation-wide population-based study. They estimated the cumulative incidences of rectal carcinoma at 1.6% at 10 years and at 5.6% at 20 years after IRA for UC.
14 Regarding the estimated incidences according to IBD duration, in the metaanalysis of Derikx et al. (a pooled analysis of three studies), the long-term estimations of incidence of post-IRA rectal carcinoma were higher than those in our study: 0%, 5% and 10% compared with 0.4%, 3.1% and 7% at 10, 20 and 30 years after IBD diagnosis, respectively. 9 In our study, the large number of patients followed for a long period of time may explain that the long-term incidences that we observed were not over-estimated, which could be the case in smaller cohorts, particularly with a shorter follow-up. Conversely, our numbers might be overestimated compared with population-based studies as our study mainly involved more severe patients followed in tertiary centers. However, our cohort may be able to provide more accurate, deeper insights regarding risk factors.
Regarding the risk of carcinoma following IPAA and as expected, the overall cumulative incidence of pouch carcinoma after IPAA is lower than the risk of rectal carcinoma after IRA. It has been reported by Derikx et al. at 1.4% at 10 years and at 3.3% at 20 years after IPAA confection. 15 Interestingly, it was estimated at 0.1% at 10 years and at 0.1% at 20 years in the Swedish population-based study. 14 Unfortunately, we couldn't compare the incidence of rectal cancer following IRA with the incidence of pouch carcinoma following IPAA in a complementary GETAID cohort, as this is currently not available.
Similarly to the risk for colonic carcinoma in the context of inflammatory colitis, 5 we determined that age and disease duration at the time of IRA as well as the concomitant presence of PSC were independently associated with the risk of developing rectal carcinoma after IRA for UC. PSC is thus highly associated with the risk of colorectal carcinoma in the context of IBD, before as well as after colectomy. This may also be the case in the context of IPAA. 16 It has been stated that endoscopic surveillance is required in the context of IRA for UC. 5, 17, 18 However there are no current guidelines available regarding the recommended frequency. The earliest rectal carcinoma occurred after 9.7 years of IBD duration in our cohort and, similarly to what it is recommended for colon screening in IBD, a rectal endoscopy screening doesn't seem necessary in the early years of the disease. Conversely, we observed the earliest rectal carcinoma 1 year after the IRA confection, so rectal neoplasia screening might be required even a short time after IRA. A reasonable approach for a screening strategy would be to follow current guidelines regarding colonic screening in IBD i.e. based on IBD duration. The relatively low overall risk of rectal carcinoma in the absence of risk factors may allow rectal endoscopies to be performed every 2 to 3 years. However in the presence of risk factors, including PSC and prior colonic neoplasia, a higher frequency of rectal surveillance seems necessary. Nevertheless, either IPAA or end ileostomy should be considered as the preferential approach after colectomy for UC in patients presenting such risk factors for colorectal carcinoma.
Unfortunately, we were not able to determine whether other known colonic carcinoma-associated factors for IBD, such as chronic inflammation and the use of treatments, influence the risk of rectal carcinoma after IRA. Additional studies are warranted for assessing these factors in order to determine a more tailored approach for rectal surveillance after UC.
While our study provides informative findings regarding the risk of rectal neoplasias after IRA for UC, some limitations have to be discussed. First, grading of dysplasias and centralized pathologic examinations have not been performed. As exposed in the Materials and Methods section, the wide period of the study did not allow us to do this. However, we selected a strong primary end point, i.e. rectal carcinoma, and we considered separately colonic dysplasia and colonic carcinoma for the risk factor analysis, which make our findings reliable. Second, data regarding surveillance [i.e. frequency and number of rectal endoscopies] was not available. Additionally, the long follow-up as well as the large number of patients followed in expert IBD centers are strong features of our cohort.
Conclusion
Rectal carcinoma may develop at a clinically relevant rate in UC patients with IRA, and this may justify regular endoscopic surveillance. The risk of rectal carcinoma is raised by a history of colonic neoplasia, IBD duration, age, and an associated diagnosis of PSC. UC patients with IRA who present one or several of the latter risk factors should be closely monitored for the risk of rectal carcinoma. Moreover, given the high risk of rectal neoplasia, either IPAA or end ileostomy should be viewed as the preferred option after colectomy for patients with PSC and/or prior colonic neoplasia, along with necessary endoscopic pouch surveillance.
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